MaxCyte is a global life sciences company applying its proprietary cell engineering technology platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. MaxCyte has placed its cutting-edge Flow Electroporation ® Technology instruments worldwide, with all of the top ten global biopharmaceuticals, and has 70+ partnered program licenses in cell therapy including 35+ licensed for clinical use. MaxCyte helps its partners to unlock the full potential of their products.